{{ 'fb_in_app_browser_popup.desc' | translate }} {{ 'fb_in_app_browser_popup.copy_link' | translate }}

{{ 'in_app_browser_popup.desc' | translate }}

【POP- UP SALE】Sanofi Respiratory Syncytial Virus (RSV) Antibody 1 Dose

【POP- UP SALE】Sanofi Respiratory Syncytial Virus (RSV) Antibody 1 Dose

Suitable for infants under 1 year or high-risk infants under 2 years
One dose only


HK$5,000.00
HK$4,380.00
Quantity Product set quantity
Add to Wishlist
The maximum quantity per submit is 99999
This quantity is invalid, please enter a valid quantity.
Sold Out

Not enough stock.
Your item was not added to your cart.

Not enough stock.
Please adjust your quantity.

{{'products.quick_cart.out_of_number_hint'| translate}}

{{'product.preorder_limit.hint'| translate}}

Limit {{ product.max_order_quantity }} per order.

Only {{ quantityOfStock }} item(s) left.

Please message the shop owner for order details.
Add to Wishlist
Description
Shipping & Payment
Customer Reviews
Description

Sanofi Respiratory Syncytial Virus (RSV) Antibody  1 Dose



Suitable for infants under 1 year or high-risk infants under 2 years.
Only one dose

RSV Long-Acting Monoclonal Antibody (Respiratory Syncytial Virus, RSV)
RSV is a common respiratory virus primarily transmitted through droplets or direct contact with infected secretions. Infants and young children are particularly vulnerable, especially those under 2 years old, with about 90% infected before age 2. RSV infection can cause acute symptoms like bronchiolitis and pneumonia, and some children may develop long-term complications, including increased risk of asthma later in life.​

Infection Risk
Infants have an extremely high risk of RSV infection—even full-term, healthy babies face significant risks comparable to preterm infants or those with chronic conditions (e.g., heart/lung disease). The 0-6 month period is especially high-risk due to immature immune systems and low antibody levels, often leading to severe pneumonia or bronchiolitis requiring hospitalization. Close contact with infected individuals, crowded environments, or family members with illness greatly increases transmission. Thus, all infants should take preventive measures to reduce infection risk and avoid long-term complications like asthma.​

The most effective and WHO-recommended prevention method currently is RSV long-acting monoclonal antibody injection, especially for newborns and high-risk groups. Compared to maternal RSV vaccination during pregnancy, direct injection into infants provides superior protection, with studies showing higher antibody levels and clinical protection rates than maternally transferred antibodies.​

Direct monoclonal antibody injection for infants offers immediate protection from birth, while maternal vaccination transfers antibodies to the fetus but with slightly shorter duration and efficacy. WHO currently recommends long-acting monoclonal antibody injection for high-risk infants and all newborns as prevention.​






* A customer who is assessed by themedical professionals to be unfit for vaccination will be refunded the amountpaid after deducting an assessment fee of HKD200.

By confirming and paying for the onlineorder, you agree that you have read these terms and conditions and accept andagree to be bound by them. 

Please adhere to the [Terms and Conditions]and [How to book] orservices may be terminated.

In case of any dispute, Kinetics Medical& Health Group Co. Ltd. reserves the right of final decision.

Shipping & Payment

Delivery Options

  • Kinetics Integrated Medical & Health Centre (Jordan)
  • Kinetics Integrated Medical & Health Centre (Causeway Bay)
  • Kinetics Integrated Medical & Health Centre (Tsuen Wan)
  • Kinetics Integrated Medical & Health Centre (By appointment)

Payment Options

  • Apple Pay
  • Credit Card (Visa/Master/Union Pay/Diner Club)
  • Alipay (HK)_SHOPLINE Payments
  • WeChat Pay
  • Payme
Customer Reviews
{{'product.product_review.no_review' | translate}}

You might also like...